Using imaging to predict and improve responses to immunotherapy
Full project names: Use of 89Zr based immune-PET to study immune checkpoint inhibitor (ICPI) therapy in head and neck cancer
Dr Gabriela Kramer-Marek
Professor Kevin Harrington.
Length of project:
The Institute of Cancer Research
In 2017, Oracle pledged funding to an exciting new research project at The Institute of Cancer Research (ICR), being undertaken under the guidance of Dr Gabriela Kramer-Marek and Oracle Honorary Trustee, Professor Kevin Harrington.
Researchers will be investigating how clinicians can use state-of-the-art imaging techniques to look at a patient’s head and neck cancer and assess whether that patient will respond to treatment with a class immunotherapies known as immune checkpoint inhibitors (ICPI).
ICPI are already being used in head and neck cancer patients and whilst results are very positive in some patients, unfortunately they are not successful in all patients.
Traditionally, treatment decisions are often based on biopsy specimens. However, we have learnt in recent years that this may not be an accurate reflection of the way that a patient’s disease will respond to treatment as different bits of the same tumour may have a slightly different genetic make-up – a phenomenon known as ‘intratumoural heterogeneity’. This means that treatments that work on one part of the tumour may not work on the whole tumour.
New techniques are needed to predict which patients will respond, but also why some patients don't respond at all.
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: Liles Morris Accountants, 1st Floor, 80 Coombe Road, New Malden KT3 4QS